FR2673106B1 - Agent de prophylaxie et de traitement pour les sequelles de la dyscrasie des neurocytes cerebraux. - Google Patents

Agent de prophylaxie et de traitement pour les sequelles de la dyscrasie des neurocytes cerebraux.

Info

Publication number
FR2673106B1
FR2673106B1 FR9202228A FR9202228A FR2673106B1 FR 2673106 B1 FR2673106 B1 FR 2673106B1 FR 9202228 A FR9202228 A FR 9202228A FR 9202228 A FR9202228 A FR 9202228A FR 2673106 B1 FR2673106 B1 FR 2673106B1
Authority
FR
France
Prior art keywords
sequelles
prophylaxis
treatment agent
dyscrasia
cerebral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9202228A
Other languages
English (en)
Other versions
FR2673106A1 (fr
Inventor
Murata Sakae
Kobayashi Tsutomu
Yamauchi Rikako
Yamaguchi Isao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Publication of FR2673106A1 publication Critical patent/FR2673106A1/fr
Application granted granted Critical
Publication of FR2673106B1 publication Critical patent/FR2673106B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
FR9202228A 1991-02-26 1992-02-26 Agent de prophylaxie et de traitement pour les sequelles de la dyscrasie des neurocytes cerebraux. Expired - Fee Related FR2673106B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11706191 1991-02-26

Publications (2)

Publication Number Publication Date
FR2673106A1 FR2673106A1 (fr) 1992-08-28
FR2673106B1 true FR2673106B1 (fr) 1995-06-16

Family

ID=14702461

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9202228A Expired - Fee Related FR2673106B1 (fr) 1991-02-26 1992-02-26 Agent de prophylaxie et de traitement pour les sequelles de la dyscrasie des neurocytes cerebraux.

Country Status (10)

Country Link
EP (1) EP0501442B1 (fr)
JP (1) JPH0586043A (fr)
KR (1) KR920016099A (fr)
AT (1) ATE131057T1 (fr)
CA (1) CA2061353A1 (fr)
DE (1) DE69206447T2 (fr)
DK (1) DK0501442T3 (fr)
ES (1) ES2083605T3 (fr)
FR (1) FR2673106B1 (fr)
GR (1) GR3018320T3 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103816462A (zh) * 2012-11-16 2014-05-28 丁徽 一种治疗中风偏瘫的中药

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85257A (en) * 1987-02-10 1993-02-21 Tanabe Seiyaku Co Pharmaceutical compositions containing 2-(4-methoxyphenyl) 3-acetoxy-5-- (2-(dimethylamino) ethyl) -8-chloro-2,3- dihydro-1,5-benzothiazepin -4 (5h)-one having renal function-improving effect and diuretic effect
US4879289A (en) * 1988-05-24 1989-11-07 Marion Laboratories, Inc. Method of ameliorating epileptic seizures

Also Published As

Publication number Publication date
DE69206447T2 (de) 1996-06-05
DK0501442T3 (da) 1996-01-08
FR2673106A1 (fr) 1992-08-28
ATE131057T1 (de) 1995-12-15
GR3018320T3 (en) 1996-03-31
EP0501442A1 (fr) 1992-09-02
CA2061353A1 (fr) 1992-08-27
JPH0586043A (ja) 1993-04-06
DE69206447D1 (de) 1996-01-18
EP0501442B1 (fr) 1995-12-06
KR920016099A (ko) 1992-09-24
ES2083605T3 (es) 1996-04-16

Similar Documents

Publication Publication Date Title
GR3035587T3 (en) Thienobenzodiazepine derivatives for treatment of CNS disorders.
NZ214156A (en) Quindone derivatives and pharmaceutical compositions
PT82368A (en) Substituted n-<(4-piperidinyl)alkyl> bicyclic condensed oxazol- and thiazolamines
FI891279A0 (fi) Antivirala tetrahydroimidazol /1,4/ benzodiazepin-2-oner.
EP0257992A3 (en) Prophylactic and therapeutic agents for cerebral ischemia
FR2673106B1 (fr) Agent de prophylaxie et de traitement pour les sequelles de la dyscrasie des neurocytes cerebraux.
DE3661311D1 (en) Novel guanidinomethylcyclohexancarboxylic acid compounds, processes for preparing them, and pharmaceutical compositions containing them
DK0420224T3 (da) Anthihepatopatisk middel
DE68900990D1 (en) Thioformamid-derivate.
EP0555479A4 (fr)
TW275629B (fr)
IE873442L (en) Cephalosporin derivative
ATE71364T1 (de) Fluor enthaltende vitamin-d2-derivate.
FR2598914B1 (fr) Composition prophylactique et curative pour l'arteriosclerose
TW265342B (fr)
KR890009886A (ko) 심기능 부전의 예방 및 치료제
FI933652A0 (fi) Foerfarande foer framstaellning av 1-osubstituerade 3-aminopyrroler
DK653687D0 (da) Middel til behandling af nyresygdomme
EP0450232A3 (en) P-guanidino benzoic acid derivatives for treatment of cerebrovascular contraction
FR2481697B1 (fr)

Legal Events

Date Code Title Description
ST Notification of lapse